NEW YORK (GenomeWeb News) – Transrenal molecular diagnostics company Trovagene said today that its revenues in the second quarter dropped 49 percent year over year.

The San Diego-based firm recorded revenues of $41,000 for the quarter ended June 30, down from $80,000 a year ago. Revenues for the recently completed quarter and Q2 2011 were in the form only of royalty income, and the year-over-year reduction resulted from the termination of an agreement with Sequenom in 2011, Trovagene said in its Form 10-Q filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.